Endpoint

Maximum urinary flow rate (Qmax, peak flow)

CAT:outcome/maximum-urinary-flow-ratereported in mL/s1 finding from 1 compound

What moved it

1 finding · 1 compound · by evidence strength

Compound	Direction	Findings	Strongest evidence
Serenoa repens	up	1	Evidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.

Reported to move it

1 finding

Serenoa repens — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“Compared with placebo, the HESr was associated with 0.64 (95% confidence interval [CI] -0.98 to -0.31) fewer voids/night (P < 0.001) and an additional mean increase in Qmax of 2.75 mL/s (95% CI 0.57 to 4.93; P = 0.01).”
Quoted verbatim from Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies..
Study

meta-analysis
Dose

320 mg daily
Population

Men with LUTS/BPH; hexanic extract of Serenoa repens (HESr, Permixon) 320 mg daily vs placebo, pooled across RCTs and observational studies.
Effect 2.75 mean difference, 95% CI 0.57 to 4.93
Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.2019PMID:29694707Permalink

How it is measured

Peak urinary flow rate by uroflowmetry, on a void exceeding the study's stated minimum voided volume. The minimum voided volume is recorded with each finding, because flow rate is volume-dependent below roughly 150 mL.

Sources cited

1 paper

Subject: maximum urinary flow rate (qmax, peak flow)
Findings: 1
Papers: 1

Efficacy and safety of a hexanic extract of Serenoa repens (Permixon® ) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (LUTS/BPH): systematic review and meta-analysis of randomised controlled trials and observational studies.record2019PMID:296947071 finding